Ganirelix
- Atc Codes:H01CC01
- CAS Codes:129311-55-3#124904-93-4
- PHARMGKB ID:129311-55-3#124904-93-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Orgalutran; Belgium: Orgalutran; Bulgaria: Orgalutran; Cyprus: Orgalutran; Czech Republic: Orgalutran; Denmark: Orgalutran; Estonia: Orgalutran; Finland: Orgalutran; France: Orgalutran; Germany: Orgalutran; Greece: Orgalutran; Hungary: Orgalutran; Ireland: Orgalutran; Italy: Orgalutran; Latvia: Orgalutran; Malta: Orgalutran; Netherlands: Orgalutran; Poland: Orgalutran; Portugal: Orgalutran; Romania: Orgalutran; Slovakia: Orgalutran; Slovenia: Orgalutran; Spain: Orgalutran; Sweden: Orgalutran; UK: Orgalutran.
North America
Canada: Orgalutran; USA: Ganirelix.
Latin America
Argentina: Orgalutran; Brazil: Orgalutran; Mexico: Orgalutran.
Drug combinations
Chemistry
Ganirelix Acetate: C~80~H~113~ClN~18~O~13~ 2C~2~H~4~O~2~. Mw: 1690.42. (1) D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N^6^-[(ethylamino)(ethylimino)methyl]-D-lysyl-L-leucyl-N^6^-[(ethylamino)(ethylimino)methyl]-L-lysyl-L-prolyl-, diacetate; (2) N-Acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N^6^-(N,N’-diethylamidino)-D-lysyl-L-leucyl-N^6^-(N,N’-diethylamidino)-L-lysyl-L-prolyl-D-alaninamide diacetate. CAS-129311-55-3; CAS-124904-93-4 (ganirelix)(1991).
Pharmacologic Category
Gonadotropin-releasing Hormone Antagonists. GnRH Antagonist. (ATC-Code: H01CC01).
Mechanism of action
Competitively blocks gonadotropin-release hormone receptors on pituitary gonadotroph and transduction pathway. This suppresses gonadotropin secretion and luteinizing hormone secretion preventing ovulation until follicles are of adequate size.
Therapeutic use
Used as component of infertility regimens (recombinant FSH, ganirelix, and human chorionic gonadotropin) to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation.
Pregnancy and lactiation implications
May cause fetal harm. Embryolethality and fetal mortality demonstrated in animals. Congenital anomalies reported in women who received ganirelix during pregnancy. Not known whether drug is distributed into milk. Use not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to ganirelix or any component of the formulation. Hypersensitivity to gonadotropin-releasing hormone or any other analog. Known or suspected pregnancy.
Warnings and precautions
The possibility of GnRH hypersensitivity exists. Packaging components contain natural rubber latex. Not intended for use in pediatric patients.